EN DE
Watch ContextVision AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ContextVision AB (CONTX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of ContextVision AB stock NOK 0.94, price NOK 4.60, that is 79.6% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare NO · Home Sweden · ISIN SE0014731154

CA ContextVision AB logo Thin data Nov 8, 2026

ContextVision AB

CONTX · OL
Solid, but very expensive

Our calculation puts a fair price 80% below what the stock costs today.

Solidly profitable · 14.0% net margin (TTM)
Generates free cash flow
Last quarter vs. a year ago: revenue +15%, profit +30%.
Quality 53/100
Mixed vs. peers (5/12)
Moderate moat 55/100 · thin data
Fair value kr 0.9400 · Strongly overvalued
Weak Growth (revenue 3y −2.2 %/yr in SEK)
Thin data
Watch ContextVision AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 25.95 kr 2.84 Fair Value kr 0.9400 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range kr 2.84 – kr 25.95 · fair‑value band kr 0.9400 – kr 0.9500 · the kr 4.60 price screens above the kr 0.9400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow ContextVision in your weekly email

Every Wednesday you see whether ContextVision is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ContextVision AB (publ), a software company, provides image analysis and imaging for medical systems in South Korea, China, Japan, the United States, and internationally.

Show moreShow less

The company offers image quality solutions for ultrasound, as well as its Rivent platform comprising Rivent, a 2D image enhancement; Rivent Plus, a premium 2D image enhancement product; Rivent 3D, a solution for improving image quality of 3D ultrasound; and Rivent Mobile, a 2D image enhancement for handheld devices for diagnostics in various fields, including radiology, cardiology, women's health, veterinary medicine, and point of-care applications.

It also provides Altumira platform, which features scatter correction and improves radiography by enabling radiation dose reduction while enhancing image quality, such as Altumira for static applications; and Altumira Plus for dynamic applications.

In addition, the company offers image quality solutions for MRI including GOPView MRI2Plus for the requirements of each application, sequence type, and protocol; and implementation projects, software updates, and upgrades and product support services.

It has a strategic clinical development partnership with the University of Washington to identify a multiparametric biomarker for the screening and staging of the liver disease MASLD; and research partnership with AMRA Medical.

ContextVision AB (publ) was incorporated in 1989 and is headquartered in Stockholm, Sweden.

Stock analysis

ContextVision AB (CONTX) currently trades at kr 4.60, while our model-based Fair Value estimate is kr 0.9400, 80% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of kr 1.07 per share, and 1 of the 22 models we run sit above the kr 4.60 price.

Bear case: the Earnings-Based group reads lowest at kr 0.1800, and 21 of the 22 models stay below the price. Data coverage for this calculation is low.

Scenario range: kr 0.9400 (bear) to kr 0.9500 (bull), the price of kr 4.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

ContextVision AB reported revenue of 110M SEK in FY2025 versus 98.1M SEK in FY2021, a compound +3.0%/yr. Reported net income was 787K SEK in FY2025.

Key figures

Market cap 356M NOK (≈ $37.7M) Micro · P/E ratio 23.0 · P/S ratio 3.43 · EPS (TTM) kr 0.2000 · Net margin 14.0% · Return on equity 18.4% · Return on assets (EBIT) 28.9% (5-year average) · Revenue (TTM) 109M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 62% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −80%, CONTX screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (kr 0.0500 to kr 5.27). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 0.9400 Fair Value kr 0.9400 Bull kr 0.9500
Price kr 4.60 · Downside -79.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.1715 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF kr 0.9700 kr 1.00 kr 1.05 78
Growth DCF kr 0.9700 kr 1.00 kr 1.05 75
Owner Earnings kr 1.01 kr 1.07 kr 1.16 73
All 22 models by family
DCF Models
FCF DCF kr 0.9700 kr 1.00 kr 1.05 78
Owner Earnings kr 1.01 kr 1.07 kr 1.16 73
5Y Revenue Exit kr 0.9600 kr 0.9900 kr 1.02 69
5Y EBITDA Exit kr 1.53 kr 2.01 kr 2.56 71
5Y P/E Exit kr 1.03 kr 1.11 kr 1.19 67
10Y Revenue Exit kr 0.9600 kr 0.9900 kr 1.02 64
10Y EBITDA Exit kr 1.33 kr 1.71 kr 2.20 65
10Y P/E Exit kr 1.01 kr 1.07 kr 1.15 61
Earnings-Based
Graham-Dodd kr 0.0700 kr 0.1800 kr 0.2400 63
PEG = 1.0 kr 0.0300 kr 0.0500 kr 0.0600 55
EPV kr 0.9400 kr 0.9400 kr 0.9500 70
Multiples
P/E Multiple kr 0.1700 kr 0.2300 kr 0.2800 63
P/S Multiple kr 0.1300 kr 0.1700 kr 0.2200 58
P/B Multiple kr 3.95 kr 5.27 kr 6.59 55
EV/EBIT kr 0.9000 kr 0.9300 kr 0.9500 63
EV/EBITDA kr 1.85 kr 2.19 kr 2.53 64
EV/Revenue kr 0.8800 kr 0.9000 kr 0.9200 52
Asset-Based
NCAV (Graham) kr 0.5800 kr 0.8900 kr 1.11 52
Growth DCF
Growth DCF kr 0.9700 kr 1.00 kr 1.05 75
Economic Profit
Residual Income kr 0.7500 kr 0.7800 kr 0.8300 68
ROIC Compounder kr 0.9400 kr 0.9400 kr 0.9500 68
Growth Earnings
Growth-Adj P/E kr 0.1300 kr 0.1900 kr 0.2400 66

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 44
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 36
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 51
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Start year 2020 (pandemic). Over 10 years: +4.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−39.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−39.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−39.5% vs −17.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 0%
Pace: the 5-year rate starts in 2020 (pandemic)

CONTX screens overvalued: fair value 80% below the price. Compare with Veeva Systems Inc →

Compare ContextVision AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −79.6% · Bottom 25%
Profitability
Return on equity (12 months) 18.4% · Top 25%
Return on assets 0.6% · Below median
Net margin (12 months) 14.0% · Top 25%
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 15.0% · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 23.0× · Cheaper than median
P/B 4.04× · Pricier than median
P/S (12 months) 3.43× · Pricier than median
EV/EBITDA 13.0× · Cheaper than median
PEG 4.07× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)75 · sector 46
PAST (return on equity)74 · sector 10
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $303.73 $334.10 +10% vs CONTX
HealthEquity, Inc HQY $103.63 $113.99 +10% vs CONTX
Doximity, Inc DOCS $32.51 $35.76 +10% vs CONTX
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs CONTX
Waystar Holding WAY $28.35 $29.10 +3% vs CONTX
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs CONTX
Pro Medicus Limited PME A$205.49 A$85.12 −59% vs CONTX
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs CONTX
XtalPi Holdings 2228 HK$6.13 HK$1.53 −75% vs CONTX
Privia Health Group PRVA $24.42 $5.52 −77% vs CONTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ContextVision AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ContextVision AB Fair Value". https://www.fairvalue-calculator.com/stock/CONTX

Frequently asked questions

Is ContextVision AB (CONTX) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of kr 0.9400 versus a price of kr 4.60, about 80% lower (overvalued).
What is the fair value of CONTX?
Our model-based fair value for ContextVision AB is kr 0.9400 (as of Nov 8, 2026), built from audited fundamentals. The current price: kr 4.60.
What is the quality score of CONTX?
ContextVision AB has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ContextVision AB (CONTX)?
Our model-based price target is the fair value of kr 0.9400 (as of Nov 8, 2026) from 22 valuation models. Cautious scenario kr 0.9400, optimistic scenario kr 0.9500. It is a calculation from audited fundamentals, not an analyst target.
What is the ContextVision AB stock forecast for 2026?
Our models put fair value at kr 0.9400, about 80% lower versus a price of kr 4.60 (overvalued). Cautious scenario kr 0.9400, optimistic scenario kr 0.9500. The calculation is refreshed regularly with new filings.
What is the revenue of ContextVision AB (CONTX)?
ContextVision AB reported trailing-twelve-month revenue of about 109M SEK (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of ContextVision AB (CONTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ContextVision AB it is kr 0.9400 per share (as of Nov 8, 2026), against a price of kr 4.60. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is ContextVision AB stock overvalued or undervalued in 2026?
As of Nov 8, 2026, CONTX trades above its calculated fair value: price kr 4.60, fair value kr 0.9400, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CONTX?
No. The price is what the market pays today (kr 4.60); the fair value is what the company's own numbers justify (kr 0.9400). For ContextVision AB the two are kr 3.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is ContextVision AB worth?
The market values ContextVision AB at about 356M NOK (market capitalisation, as of Nov 8, 2026). Per share that is kr 4.60; our models calculate a fair value of kr 0.9400 per share.
What do the bullish and bearish scenarios say about CONTX?
Our models span a range for ContextVision AB: cautious scenario kr 0.9400, base kr 0.9400, optimistic kr 0.9500 per share (as of Nov 8, 2026, price kr 4.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CONTX?
ContextVision AB trades at a price-to-earnings ratio of 23.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 0.9400 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2020 to 2025), reported earnings: 26.2. Other multiples: PEG 4.1, P/B 4.0, P/S 3.4, EV/EBITDA 13.0.
What is the PEG ratio of CONTX?
The PEG ratio of ContextVision AB is 4.07 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of ContextVision AB (CONTX)?
Balance-sheet figures for ContextVision AB (as of Nov 8, 2026): return on equity 18.4%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is CONTX from its 52-week high?
ContextVision AB trades at kr 4.60, about 19% below its 52-week high of kr 5.70 and 62% above the low of kr 2.84 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.9400 is for.
Which stocks are comparable to ContextVision AB?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ContextVision AB stock attractive at the current price?
The data as of Nov 8, 2026: price kr 4.60, calculated fair value kr 0.9400 (−80%), Quality Score 53/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CONTX calculated?
We run ContextVision AB through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 0.9400 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ContextVision AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ContextVision AB (CONTX)?
The closing price on Nov 6, 2026 was kr 4.60. Our model-based fair value is kr 0.9400, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ContextVision AB right now?
The price sits above even our optimistic bull case (kr 0.9500). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (kr 0.9400 to kr 0.9500), unusually little disagreement for a valuation.
Where does the earnings growth of ContextVision AB (CONTX) come from?
Earnings per share at ContextVision AB grew +20.9 % a year from 2013 to 2024. Broken into its drivers: revenue per share +7.5 %, EBIT margin +12.5 %, tax rate +0.3 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of ContextVision AB

How large is the market capitalisation of ContextVision AB (CONTX)?
The market capitalisation of ContextVision AB is 356M NOK (≈ $37.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ContextVision AB (CONTX)?
The price-to-sales ratio of ContextVision AB is 3.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ContextVision AB (CONTX)?
Earnings per share at ContextVision AB are kr 0.2000 (price ÷ EPS = P/E 23.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ContextVision AB (CONTX)?
The net margin of ContextVision AB is 14.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ContextVision AB (CONTX)?
The return on equity (ROE) of ContextVision AB is 18.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ContextVision AB (CONTX)?
On an EBIT basis the return on assets of ContextVision AB is 28.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at ContextVision AB (CONTX)?
Revenue at ContextVision AB is growing +15.0% versus a year earlier (3y avg −2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ContextVision AB (CONTX)?
Earnings per share at ContextVision AB are growing +30.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ContextVision AB (CONTX) generate?
The free cash flow of ContextVision AB is 202K SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ContextVision AB (CONTX) hold?
ContextVision AB holds more cash than debt, 63.9M SEK net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ContextVision AB in the live analysis

One click puts ContextVision AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.